JSH-23 is primarily used in biomedical research as a selective inhibitor of the NF-κB signaling pathway. It is commonly applied in studies related to inflammation, immune response, and cancer due to its ability to block nuclear translocation of the NF-κB p65 subunit. This inhibition reduces the expression of pro-inflammatory cytokines and other genes regulated by NF-κB, making JSH-23 a valuable tool in exploring therapeutic strategies for inflammatory diseases and tumor progression. It is frequently used in cell-based assays to assess the role of NF-κB in cellular processes and to evaluate potential anti-inflammatory or anti-cancer agents.